A Unique Model for Treating Chronic Hepatitis C in Patients With Psychiatric Disorders, Substance Abuse, and/or Housing Instability

被引:16
|
作者
Ho, Cheryl J. [1 ,3 ]
Preston, Charles [1 ]
Fredericks, Kim [1 ]
Doorley, Sara L. [1 ,3 ]
Kramer, Richard J. [2 ,3 ]
Kwan, Lawrence [1 ]
Kamal, Ahmad [2 ,3 ]
机构
[1] Santa Clara Valley Med Ctr, Dept Med, Div Primary Care, Valley Homeless Healthcare Program, San Jose, CA 95128 USA
[2] Santa Clara Valley Med Ctr, Div Gastroenterol, San Jose, CA 95128 USA
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
Hepatitis C; homeless persons; injection drug use; interdisciplinary communication; mental illness; patient-centered care; METHADONE-MAINTENANCE TREATMENT; VIRUS-INFECTED PATIENTS; ILLICIT-DRUG-USERS; INTERFERON-ALPHA; RANDOMIZED-TRIAL; PLUS RIBAVIRIN; UNITED-STATES; OUTCOMES; PROGRAM; CARE;
D O I
10.1097/ADM.0b013e31829b1a6c
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Individuals with psychiatric disease, substance abuse, and/or housing instability have a high prevalence of chronic hepatitis C virus (HCV) infection. However, such individuals are often excluded from treatment for HCV infection because of a perceived inability to adhere to the rigorous medication regimen required. Methods: A pilot program using a multidisciplinary group medical visit model to treat HCV infection in the aforementioned population was created. Medication adherence and virologic response rates were prospectively followed. Results: Approximately 80% of patients were adherent to their HCV infection treatment regimen, as measured by attendance at group medical visits and by medication adherence. A sustained virologic response rate of 55% among individuals with genotype 1 infection and 80% among individuals with genotype 2 or 3 infections was observed. These results compare favorably with those seen in large, randomized controlled trials. Rates of discontinuation and adverse effects were similar to those seen in other studies. Conclusions: An intensive, multidisciplinary treatment approach toward HCV infection treatment can achieve favorable results even in persons traditionally considered to be "poor treatment candidates." Programs aimed at bringing HCV infection treatment to this population are needed.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 50 条
  • [21] Guidelines for the management of chronic hepatitis C in patients infected after substance use
    Robaeys, G
    Buntinx, F
    Bottieau, E
    Bourgeois, S
    Brenard, R
    Colle, I
    De Bie, J
    Matheï, C
    Mulkay, JP
    Van Damme, P
    Van Ranst, M
    Verrando, R
    Michielsen, P
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2005, 68 (01): : 38 - 45
  • [22] Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C
    Theodore, D
    Fried, MW
    Kleiner, DE
    Kroner, BL
    Goedert, JJ
    Eyster, ME
    Faust, SP
    Sherman, KE
    Kessler, CM
    Francis, C
    Aledort, LM
    HAEMOPHILIA, 2004, 10 (05) : 413 - 421
  • [23] Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C
    Jiang, Xinyi
    Vouri, Scott Martin
    Diaby, Vakaramoko
    Lo-Ciganic, Weihsuan
    Parker, Robert
    Park, Haesuk
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (10) : 1388 - 1402
  • [24] Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
    de Oliveira Andrade, Luis Jesuino
    Atta, Ajax Merces
    Brito de Sousa Atta, Maria Luiza
    Kalil Mangabeira, Celia Neder
    Parana, Raymundo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (04) : 377 - 381
  • [25] HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C
    Kakizaki, S
    Takagi, H
    Murakami, E
    Takayama, H
    Mori, M
    JOURNAL OF HEPATOLOGY, 1999, 30 (05) : 794 - 800
  • [26] Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder: a commentary
    Dupouy, Julie
    Lapeyre-Mestre, Maryse
    Oustric, Stephane
    PAIN, 2017, 158 (01) : 6 - 7
  • [27] Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial
    Stahmeyer, J. T.
    Krauth, C.
    Bert, F.
    Pfeiffer-Vornkahl, H.
    Alshuth, U.
    Hueppe, D.
    Mauss, S.
    Rossol, S.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (02) : 105 - 115
  • [28] Prevalence of hepatitis C virus infection in patients with chronic mental disorders: The relevance of dual disorders
    Roncero, Carlos
    Buch-Vicente, Barbar
    Martin-Sanchez, Angel Manuel
    Alvarez-Navares, Ana Isabel
    Andres-Olivera, Pilar
    Gamonal-Limcaoco, Sinta
    Lozano-Lopez, Maria Teresa
    Aguilar, Lourdes
    Sanchez-Casado, Felisa
    Garcia-Ullan, Llanyra
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (03): : 171 - 177
  • [29] Teledermatologist expert skin advice: A unique model of care for managing skin disorders and adverse drug reactions in hepatitis C patients
    Charlston, Samuel
    Siller, Gregory
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 (04) : 315 - 317
  • [30] The Estimation of Direct Medical Costs of Treating Patients With Chronic Hepatitis B and C in Iran
    Kalantari, Hamid
    Davari, Majid
    Akbari, Mojtaba
    Hejazi, Seyed Mehdi
    Kalantari, Maryam
    Zakerin, Shahram
    Shahshahan, Zahra
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2012, 3 (03) : 191 - 196